More about Science
Choose a therapeutic area to find related scientific content
Diabetes
Dyslipedimia
Neurology
.png/jcr:content/MicrosoftTeams-image%20(16).png)
Oncology
Rare Blood Disorders
Rare Diseases
Thrombosis
Explore Content
Explore the most recently added content
Prescribing Information can be found through the links in the Product Cards at the bottom of the page
AUBAGIO® (teriflunomide) Overview: Efficacy (Brain Health) and Real-World (Patient-Reported Outcomes, Adherence, Effectiveness) - Prof. Jiwon Oh
Aubagio® (teriflunomide): MoA and Safety - Prof. Patrick Vermersch
.jpg)
Diagnosis and Misdiagnosis of MPS I
Diagnosis of Gaucher disease
Epidemiology of Gaucher disease
Fabry Disease & Cardiology
Fabry Disease and Nephrology
Gaucher disease - The patient's experience - Janet
Gaucher disease - The patient's experience - Peter
Gaucher disease - The patient's experience - Sarah
Gaucher disease Management and Specialist Treatment Centres
How can early diagnosis of new born MPS patients be achieved?
Support for your Patients
Discover the selection of support materials for patients from different therapeutic areas
MPS I Physiotherapy Flipbook
Our Products
MAT-XU-2200954 (v1.0)
Date of preparation: September 2022
---Copy.png/jcr:content/AUBAGIO_logo_RGB%20(1)%20-%20Copy.png){kind=logo}
Prescribing Information GB
Prescribing Information NI
MAT-XU-2200676 (v3.0)
Date of preparation: August 2022
.png/jcr:content/Cablivi-logo%20(3).png){kind=logo}
Prescribing Information GB
Prescribing Information NI
MAT-GB-2105168 (v2.0)
Date of preparation: November 2022
MAT-XU-2204064 (v1.0)
Date of preparation: September 2022
MAT-XU-2204065 (v1.0)
Date of preparation: September 2022
MAT-GB-2105812 (v2.0)
Date of preparation: August 2022
.png/jcr:content/Lemtrada-triangle-logo-product-card%20(1).png){kind=logo}
Prescribing Information GB
Prescribing Information NI
MAT-XU-2200680 (v2.0)
Date of preparation: August 2022
.png/jcr:content/Myozyme-logo%20(1).png){kind=logo}
MAT-GB-2105179 (v3.0)
Date of preparation: August 2022
Praluent
alirocumab
Prescribing Information GB
Prescribing Information NI
MAT-XU-2204604 (v1.0)
Date of preparation: October 2022
▼ This drug is subject to additional monitoring, the reporting of suspected adverse reactions associated with this drug is a priority.
MAT-GB-2105264 (v4.0)
Date of preparation: December 2022
